When people hear the phrase precision medicine, they often think of high-tech lab reports, complex gene panels, and cancer treatments designed for one very specific mutation. That is part of the story, but the bigger shift is even more meaningful: precision care is increasingly about preserving how people live, move, work, and feel. In other words, the goal is not only to treat disease, but also to protect function, quality of life, and confidence along the way.
That is why precision tests and single-target therapies deserve a fresh look. New evidence shows that better biomarker testing, liquid biopsy, organoid drug-response models, and function-focused treatment plans are changing how clinicians think about success. Instead of asking only, “Did the treatment shrink the disease?” more experts are also asking, “Did it help preserve daily life?”
Precision medicine starts with the right test
A practical way to understand precision medicine is this: the treatment can only be as precise as the test that guides it. The U.S. FDA has made this point clearly, noting that personalized medicine fundamentally depends on biomarkers and diagnostic tests that accurately identify which patients are most likely to benefit from a therapy. That matters because a drug may look highly effective in the right group, but less useful or more harmful in the wrong one.
For patients and families, this means testing is not just a technical step before treatment. It can shape the whole care pathway. A biomarker test may help identify whether a targeted drug is likely to work, whether a side effect risk is higher, or whether a different strategy would better protect long-term function. In simple terms, better matching can mean fewer unnecessary treatments and fewer avoidable trade-offs.
The regulatory focus on test quality is also growing. In April 2026, the FDA updated its guidance on bioanalytical method validation for biomarkers, signaling how important measurement quality remains in drug development and clinical decision-making. That may sound far removed from everyday health concerns, but it supports something very practical: if a test is going to influence major treatment choices, it needs to be reliable.
Why the one-test, one-drug model is no longer enough
For years, precision care was often described as a simple pairing: one companion diagnostic test linked to one drug. That model helped launch modern targeted therapy, and it still matters. The FDA’s companion diagnostic inventory continues to expand in 2025 and 2026, including established oncology platforms such as FoundationOne CDx and Oncomine Dx Target Test. These tools remain central to how many patients are matched to treatment.
At the same time, the field is moving beyond the idea that one test should only unlock one medicine. The National Academies has noted that the classic companion-diagnostic model may not fit a future in which one broad test can guide multiple therapies across platforms. This is a major mindset shift. Instead of repeatedly ordering narrow tests, clinicians may increasingly use wider biomarker strategies that provide a more complete picture.
That broader view is useful because real diseases are rarely one-dimensional. A tumor may carry several relevant features at once, or change over time as treatment pressure selects for resistant cells. Looking at more than one biomarker can help doctors adapt care earlier and more thoughtfully. For patients, this could mean a smoother path to treatment and fewer delays caused by fragmented testing.
Rethinking single-target therapies in a resistant world
Single-target therapies can be powerful, especially when a disease is strongly driven by one abnormal pathway. In blood cancers, for example, next-generation high-throughput sequencing has helped identify recurrent genetic events that directly influence prognosis and treatment stratification. In urothelial cancer, recent reviews highlight how FGFR inhibitors and anti-drug conjugates aimed at Nectin-4 and HER2 are reshaping treatment options, with biomarker testing often determining access.
Still, one of the biggest lessons from recent research is that a single target is not always a lasting solution. Resistance remains a major barrier. A 2026 review of KRAS-targeted therapy emphasized resistance mechanisms and the need for next-generation or combination approaches. This is a reminder that a treatment can be precise without being complete. Disease biology often adapts, and treatment plans may need to adapt too.
That is why preserving function requires more than excitement about a targeted drug. It requires a long-term strategy that considers durability, side effects, and what happens if the disease changes course. Precision care works best when it is flexible, not rigid. The smartest plan may involve a targeted therapy today, close monitoring tomorrow, and a different approach later if the biology shifts.
Liquid biopsy and MRD are changing what we measure
One of the most promising developments in precision care is the rise of liquid biopsy. Instead of depending only on tissue samples, clinicians can increasingly use blood-based testing to track disease signals over time. A 2025 review in colorectal cancer described liquid biopsy as having the potential to become a cornerstone of precision oncology, helping support earlier intervention and more tailored treatment strategies.
This matters because preserving function often depends on catching trouble early. If disease activity can be spotted before symptoms worsen or before scans show major progression, treatment can sometimes be adjusted in a more measured way. Liquid biopsy may also reduce the need for repeated invasive procedures, which is a practical benefit for patient comfort and recovery.
Minimal residual disease, or MRD, adds another important layer. In follicular lymphoma, a 2025 SWOG analysis showed that MRD status predicted outcomes after chemoimmunotherapy. That makes MRD more than a lab metric. It becomes a functional readout of whether treatment is truly delivering durable control. A therapy is not just successful because it produces an initial response; it is more meaningful when it helps preserve stability over time.
Functional precision medicine moves beyond genomics alone
Genomic testing remains valuable, but many experts now argue that genes tell only part of the story. Precision oncology is increasingly described as multiomic, functional, and aware of tumor heterogeneity rather than purely mutation-driven. Recent reviews point to liquid biopsy, multiomics, and single-cell spatial approaches as major trends, all aimed at understanding not just what a disease looks like on paper, but how it behaves in real life.
This is where functional precision medicine becomes especially interesting. A 2026 ASCO report on MicroOrganoSpheres in advanced colorectal cancer evaluated lesion-level and patient-level response prediction using a functional platform. In plain language, researchers are testing how a patient’s disease cells actually respond to drugs outside the , then comparing that information with clinical outcomes. That can complement molecular profiling and make treatment selection more grounded in observed behavior.
For readers who like practical takeaways, the idea is simple: sometimes the most useful question is not only “What mutation is present?” but also “What actually works on these cells?” That shift could help reduce trial-and-error treatment, lower exposure to ineffective therapies, and support better day-to-day functioning during care.
Organoids may help match treatment to real-life outcomes
Organoid-based testing is gaining attention because it offers a more personalized and functional window into treatment response. A 2026 review described organoid drug selection as practical precision medicine, noting that predictive accuracy rates above 90% have been shown in clinical studies. The same review suggested that organoids may help bridge tumor eradication with post-therapy functional restoration, which is exactly the kind of outcome many patients care about most.
Pancreatic cancer research offers a strong example. A 2025 review reported that patient-derived organoid functional classification predicted response in 91.1% of treatment-naive patients receiving first-line chemotherapy and 80.0% in second-line regimens. Those numbers are encouraging because pancreatic cancer is often difficult to treat, and any method that improves treatment matching could have a real impact on both outcomes and treatment burden.
Of course, organoid testing is not yet routine everywhere, and availability may differ by center. But the trend is clear: precision medicine is becoming more dynamic and more personal. Instead of relying only on static markers, doctors may increasingly combine biomarker testing with living models of response. Over time, that could support treatment plans that are both effective and less disruptive to function.
Function preservation is becoming a true treatment goal
One of the clearest examples of this new mindset appears in prostate cancer. Reviews from 2025 and 2026 describe focal therapy as a leading function-preserving precision treatment, with continence preservation above 90% and erectile-function maintenance reaching up to 100% across some modalities. These approaches are guided by imaging and biopsy to target disease more selectively while sparing more healthy tissue.
That balance is becoming central to how success is defined. A 2025 editorial described focal therapy as harmonizing cancer control with quality of life, and a 2025 systematic review and meta-analysis of prospective studies examined both oncologic and functional outcomes. This dual focus matters because many patients do not want to choose between survival and selfhood. They want the best disease control possible while protecting urinary, sexual, and emotional well-being.
The 2025 PRESERVE trial of irreversible electroporation in intermediate-risk prostate cancer reinforces this point. Functional endpoints, including urinary and sexual function, were key outcomes in the study. That is a sign of real progress. More researchers are treating function preservation as a primary objective, not a secondary bonus.
Precision care is expanding beyond classic targeted oncology
Although cancer care often gets the spotlight, the same principles are spreading more broadly. FDA pharmacogenomic biomarker labeling tables now include many drug-biomarker pairs across oncology and non-oncology uses, reflecting how precision dosing and treatment selection have become more mainstream. This means the movement toward “right treatment, right person, right time” is no longer limited to one specialty.
Companion diagnostics are also evolving into a broader technology stack. A 2026 review describes the shift from older tissue-focused methods such as IHC and FISH toward RT-PCR, next-generation sequencing, imaging-based approaches, and liquid biopsy. This wider toolkit gives clinicians more ways to gather relevant information while potentially reducing unnecessary interventions.
Even cellular therapy is showing what function-preserving precision can look like. In the 2026 Precision-T phase 3 trial, Orca-T improved graft-versus-host-disease-free and relapse-free survival while reducing moderate-to-severe chronic graft-versus-host disease compared with Tac/MTX. That is a strong example of precision strategy helping preserve patient function beyond surgery or classic drug therapy.
What patients can take from this shift
All of this science points to one encouraging message: precision tests and single-target therapies are becoming part of a bigger, more human-centered picture. The goal is increasingly to integrate the right biomarker test, the right therapy, toxicity avoidance, and function preservation. In metastatic colorectal cancer, for example, a 2025 study found higher overall health-related quality of life in patients receiving cytotoxic plus targeted therapy compared with cytotoxic therapy alone. Better matching may improve not just disease metrics, but lived experience.
If you or someone you love is navigating a major diagnosis, it can help to ask practical questions. What biomarkers have been tested? Is there a broader panel that could provide more useful information? Could liquid biopsy or MRD monitoring help track response? Are there function-preserving treatment options, such as organ-sparing or focal approaches, that are appropriate in this case? These questions can support more informed and confident conversations with a care team.
It is also okay to remember that precision care is not magic. Not every test is needed, not every targeted drug works forever, and not every promising technology is widely available yet. But the direction is hopeful. Medicine is becoming more focused on preserving the parts of life that matter most, and that is a meaningful kind of progress.
In the end, rethinking how we preserve function means rethinking what successful treatment really looks like. It is no longer enough to celebrate a narrower therapy simply because it is more targeted. We also have to ask whether it protects long-term health, reduces harm, supports independence, and helps people maintain dignity and quality of life.
That is why precision tests matter so much. They are not just tools for sorting patients into treatment categories. They are becoming the foundation for smarter, gentler, and more adaptive care. As precision medicine continues to evolve, the most valuable breakthroughs may be the ones that help people not only live longer, but live better.
